Navigation Links
Delcath Strengthens Research and Development Team with Key Appointments
Date:10/20/2010

was previously Principal Research Scientist in the Translational Medicine group at Pfizer, Inc. In this role, he identified and validated pharmocodynamic and patient selection biomarkers for preclinical and clinical assets and guided clinical development and asset differentiation.  Dr. Johnston also served as Chair for the Oncology Early Biomarker Strategy Team at Pfizer. Prior to joining Pfizer, he was a Senior Research Scientist for Wyeth's Women's Health Research group, where he was a project team leader for three small molecule drug development projects. He earned his PhD at The Johns Hopkins University Bloomberg School of Public Health and completed his postdoctoral research at the School of Molecular Biosciences at Washington State University.

About Delcath Systems

Delcath Systems, Inc. is a development stage, specialty pharmaceutical and medical device company focused on oncology. Delcath's proprietary system for chemosaturation is designed to administer high dose chemotherapy and other therapeutic agents to diseased organs or regions of the body, while controlling the systemic exposure of those agents. The Company's initial focus is on the treatment of primary and metastatic liver cancers. In 2010, Delcath concluded a Phase III metastatic melanoma study, and the Company recently completed a multi–arm Phase II trial to treat other liver cancers. The Company has not yet received FDA or any foreign regulatory approval for commercial sale of its system. For more information, please visit the Company's website at www.delcath.com.

The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward–looking statements made by the Company or on its behalf. This news release contains forward–looking statements, which are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Fa
'/>"/>

SOURCE Delcath Systems, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Delcath Signs Agreement With Synerx and Mylans Bioniche Teoranta for Melphalan Supply
2. Delcath to Present at the William Blair Emerging Growth Stock Conference
3. Delcath to Present at the JMP Securities Healthcare Conference
4. Delcath Systems Announces Completion of Common Stock Offering
5. Delcath to Present at the 30th Annual Canaccord Global Growth Conference
6. Delcath to Present at the 2010 Wedbush Securities Life Sciences Best Ideas Management Access Conference
7. Delcath Systems Announces Second Quarter Progress Report Conference Call
8. Delcath Reconfirms Presentation During American Society of Clinical Oncology 2010 Annual Meeting in Chicago
9. Delcaths Eamonn Hobbs to Ring NASDAQ Opening Bell
10. Delcath Systems Provides Update on Corporate Developments
11. Delcath Signs First Partner Agreement in Asia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... July 30, 2015  Cardinal Health today reported ... an increase of 20 percent, and non-GAAP diluted ... $1.00, an increase of 20 percent. Non-GAAP operating ... a GAAP basis, operating earnings increased 44 percent ... operations increased 29 percent to $0.88. ...
(Date:7/30/2015)... ST. PAUL, Minn. , July 30, 2015 /PRNewswire/ ... of medical devices using neuroblocking technology to treat obesity, ... it will host a conference call on Thursday, August ... financial results for the second quarter ended June 30, ... of the Company,s vBloc® Neurometabolic Therapy, delivered via the ...
(Date:7/30/2015)... 2015   HeartWare International, Inc . (NASDAQ: ... invasive, miniaturized circulatory support technologies that are revolutionizing ... total revenue of $73.6 million for the quarter ... for the quarter ended June 30, 2014.  Currency ... or nine percentage points, during the three months ...
Breaking Medicine Technology:Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 2Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 3Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 4Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 5Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 6Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 7Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 8Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 9Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 10Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 11Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 12Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 13Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 14Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 15Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 16Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 17Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 18Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 19Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 20Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 21Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 22Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 23Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 24Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 25Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 26Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 27Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 28Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 29Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 30Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 31Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 32Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 33Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 34Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 35Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 36
... Sept. 22, 2011 Biodel Inc. (Nasdaq: BIOD ... Chief Executive Officer, will be presenting at the 6th Annual ... New York.  The presentation is scheduled for Tuesday, September 27, ... to the live webcast or a replay of the presentation, ...
... Sept. 22, 2011 Reportlinker.com announces that ... in its catalogue: Generic ... http://www.reportlinker.com/p0619265/Generic-Drugs-The-Global-Market--Focus-on-Europe.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Machine_Tool_and_Equipment ... * An examination of the strategies employed ...
Cached Medicine Technology:Generic Drugs: The Global Market--Focus on Europe 2Generic Drugs: The Global Market--Focus on Europe 3Generic Drugs: The Global Market--Focus on Europe 4Generic Drugs: The Global Market--Focus on Europe 5Generic Drugs: The Global Market--Focus on Europe 6Generic Drugs: The Global Market--Focus on Europe 7Generic Drugs: The Global Market--Focus on Europe 8Generic Drugs: The Global Market--Focus on Europe 9Generic Drugs: The Global Market--Focus on Europe 10
(Date:7/30/2015)... ... 30, 2015 , ... The New Jersey Innovation Institute (NJII), ... of Health, has received a $2.9 million grant from the Office of the ... Health and Human Services (HHS). NJII will help the Department of Health ensure ...
(Date:7/30/2015)... ... July 30, 2015 , ... The ... Cancer Institute Designation , The Tisch Cancer Institute (TCI) at the Icahn School ... cancer center. TCI joins an elite group of 69 cancer institutions nationwide that ...
(Date:7/30/2015)... ... ... New research finds some distinct differences in the way mesothelioma behaves in ... Mesothelioma website. , Researchers with the National Institutes of Health, the FDA, and ... occurring between 1990 and 2010. Two percent of these cases (207) occurred in people ...
(Date:7/30/2015)... ... July 30, 2015 , ... InventHelp, a leading inventor service ... personal-care device that makes it easy to apply lotion or medication to a hard-to-reach ... assistance when applying lotion or medication to the back, and provides thorough coverage. The ...
(Date:7/30/2015)... CA (PRWEB) , ... July 30, 2015 , ... Bird ... offers a new bird hazing system to repel pest birds from the ... 60 diseases—including histoplasmosis, encephalitis, salmonella, meningitis, and toxoplasmosis, even the West Nile virus. When ...
Breaking Medicine News(10 mins):Health News:New Jersey Innovation Institute Awarded $2.9 Million Federal Grant to Advance Health Information Technology Services to Support Health Information Exchange 2Health News:The Tisch Cancer Institute at Icahn School of Medicine at Mount Sinai Earns National Cancer Institute Designation 2Health News:The Tisch Cancer Institute at Icahn School of Medicine at Mount Sinai Earns National Cancer Institute Designation 3Health News:The Tisch Cancer Institute at Icahn School of Medicine at Mount Sinai Earns National Cancer Institute Designation 4Health News:The Tisch Cancer Institute at Icahn School of Medicine at Mount Sinai Earns National Cancer Institute Designation 5Health News:The Tisch Cancer Institute at Icahn School of Medicine at Mount Sinai Earns National Cancer Institute Designation 6Health News:Study Finds Mesothelioma Behaves Differently in Younger People, According to Surviving Mesothelioma 2Health News:InventHelp® Client Patents “My Back Buddy” – Device Could Apply Lotion to Hard-to-Reach Areas Easily 2Health News:Bird B Gone’s New Bird Hazing System Keeps Disease-Carrying Bird Droppings Out of Hospitals 2
... de Montréal and the Centre hospitalier de l’Université de ... the// human immunodeficiency virus (HIV). For the first time, ... to HIV and found a way to correct the ... biology, immunology, and virology, has confirmed the identification of ...
... epidemic proportions in Gujarat according to the government there ... any part of flood-ravaged Surat.// ,Quoting the ... State Health Secretary Amarjit Singh, Delhi, said that all ... rodent samples for plague as well as for Hantavirus ...
... emotional debate, US health authorities have approved the sale ... women 18 years and older.// ,But girls ... the Food and Drug Administration said Thursday. ... contained in birth control pills, interrupts pregnancy if used ...
... Scientists at the Indian Council of Agricultural Research (ICAR) have ... for diabetics because of its low caloric// content. ... blood can be developed from this new 'Dicoccum' variety of ... the Dharwad center of University of Agricultural Sciences developed the ...
... compound called rasfonin has been synthesized from a fungus for ... a New Zealand cave cave. //A chemical found in this ... harming healthy cells. ,"In 2000, scientists in Japan ... a prototype anticancer agent, but no one has been able ...
... in the center of attention now a days experts have ... actually be too fat //for their own good. ... coming from several top health groups, like the World Health ... the American Academy of Pediatrics as to if baby fat, ...
Cached Medicine News:Health News:Researchers Make a Major Strategic Breakthrough in Controlling the AIDS Virus 2Health News:Cancer-Killing Compound From A Fungus 2Health News:Chubbiness In Babies Might Not Be A Cute Sign 2
...
... Retriever is for arthroscopic and open soft tissue ... complicated procedural steps. It may be used ... and in conjunction with,anchors or screws (including suture ... needle tip permits the placement of a variety ...
The Nordt Knot Tightener allows both pushing and spreading of knots, reproducing identical techniques,used when tying traditional open knots. The Nordt Knot Tightener allows tying of any type of s...
Single step suture passage is made simple with Arthro-Pierce instruments. The low profile, highly sharpened tip allows easy passage through tissue in order to retrieve or apply suture....
Medicine Products: